A Randomized, Open-label Study Comparing the Systemic Exposure to Triamcinolone Acetonide Following a Single Intra-articular Dose of Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) in Patients With Osteoarthritis of the Shoulder (Glenohumeral Joint) or Hip

Trial Profile

A Randomized, Open-label Study Comparing the Systemic Exposure to Triamcinolone Acetonide Following a Single Intra-articular Dose of Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) in Patients With Osteoarthritis of the Shoulder (Glenohumeral Joint) or Hip

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 May 2018

At a glance

  • Drugs Triamcinolone (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms SHIP
  • Sponsors Flexion Therapeutics
  • Most Recent Events

    • 18 Dec 2017 According to a Flexion Therapeutics media release, approximately 48 patients in total will be enrolled, including 24 patients with OA of the shoulder and 24 patients with OA of the hip.
    • 18 Dec 2017 According to a Flexion Therapeutics media release, first patient has been enrolled, and topline data is expected in the second half of 2018.
    • 18 Dec 2017 Status changed from planning to recruiting, according to a Flexion Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top